Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IDEAYA Biosciences, Inc.

Get SEC filing alerts via email and in your feed for IDEAYA Biosciences, Inc.

IDYA

IDEAYA Biosciences, Inc.

About IDEAYA Biosciences, Inc.

Ideaya Biosciences is a precision medicine oncology company developing targeted small molecule therapeutics and companion diagnostics for genetically defined cancers. Its pipeline includes clinical-stage candidates targeting PKC, MAT2A, DLL3, Pol Theta Helicase, PARG, and KAT6/7, with a focus on biomarker-driven patient populations. The company collaborates with leading pharma firms, owns extensive proprietary platforms, and aims to address unmet needs in cancer treatment through innovative, targeted therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IDEAYA Biosciences, Inc.

1
1
IDEAYA Biosciences, Inc. IDEAYA Biosciences Reports $6.6M Collaboration Revenue and $98.5M Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
IDEAYA Biosciences, Inc. IDEAYA Biosciences Reports $218.7M Collaboration Revenue Increase and $113.7M Net Loss for 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
IDEAYA Biosciences, Inc. IDEAYA Biosciences Reports $207.8M Collaboration Revenue and $119.2M Net Income for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IDEAYA Biosciences, Inc. IDEAYA Biosciences Reports $77.5 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IDEAYA Biosciences, Inc. IDEAYA Biosciences Reports $72.2 Million Net Loss in Q1 2025 Amid Increased R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IDEAYA Biosciences, Inc. IDEAYA Biosciences Reports $274.5 Million Net Loss and Significant Revenue Decline in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
IDEAYA Biosciences, Inc. Ideaya Biosciences Reports Strong Financial Position, Increased R&D Expenses, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments